

IN THE CLAIMS:

Claim 20 is canceled. Claim 12 has been amended herein. New claims 22 through 25 are to be added. All of the pending claims 1 through 19 and 21 through 25 are presented herein. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Withdrawn) An isolated, synthetic or recombinant peptide of a minor Histocompatibility antigen HA-1 origin, the isolated, synthetic or recombinant peptide comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X is histidine or arginine.
2. (Withdrawn) The isolated, synthetic or recombinant peptide of claim 1, wherein X is histidine.
3. (Withdrawn) The isolated, synthetic or recombinant peptide of claim 1, wherein the isolated, synthetic or recombinant peptide has a length of about 7 to 15 amino acids.
4. (Withdrawn) A vaccine comprising the isolated, synthetic or recombinant peptide of claim 1.
5. (Withdrawn) A composition comprising the isolated, synthetic or recombinant peptide of claim 1.
6. (Withdrawn) A process of inducing tolerance for transplants to reduce the rejection and/or Graft versus Host disease or to treat autoimmune disease in a subject, the process comprising:
administering the isolated, synthetic or recombinant peptide of claim 1 to a subject.

7. (Withdrawn) The process according to claim 6, wherein the isolated, synthetic or recombinant peptide is administered orally, intravenously, intraocularly, intranasally, or combinations of any thereof.

8. (Withdrawn) A process for the elimination of hematopoietic cells presenting a peptide of an HLA class 1 origin, the process comprising:
inducing cytotoxic T-cells with the isolated, synthetic or recombinant peptide of claim 1; and
placing the induced cytotoxic T-cells in contact with hematopoietic cells presenting the peptide of the HLA class 1 origin.

9. (Withdrawn) An analog of the isolated, synthetic or recombinant peptide of claim 1, wherein the analog is an antagonist for the activity of T cells recognizing the isolated, synthetic or recombinant peptide.

10. (Withdrawn) A process for producing antibodies, T-cell receptors, anti-idiotypic B-cells or T-cells, the process comprising:
administering the isolated, synthetic or recombinant peptide of claim 1 to a mammal, thus
inducing production of the antibodies, T-cell receptors, anti-idiotypic B-cells or T-cells.

11. (Withdrawn) Antibodies, T-cell receptors, B-cells or T-cells produced by the process according to claim 10.

12. (Currently amended) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide having up to fifteen (15) amino acids and comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X represents histidine or arginine;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and
contacting a hematopoietic cell with the ~~isolated, synthetic or recombinant peptide~~
antigen presenting cell, thus, producing the cytotoxic T-cell.

13. (Previously presented) The process according to claim 12, wherein the hematopoietic cell is negative for the minor antigen.

14. (Previously presented) The process according to claim 12, wherein the minor antigen is HA-1.

15. (Previously presented) The process according to claim 12, wherein contacting the hematopoietic cell with the isolated, synthetic or recombinant peptide is carried out ex vivo.

16. (Previously presented) The process according to claim 12, further comprising transducing the cytotoxic T-cell with a suicide gene.

17. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is immortalized.

18. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is capable of expansion.

19. (Previously presented) A cytotoxic T-cell, produced by the process according to claim 12.

20. (Canceled).

21. (Withdrawn) An immunogenic polypeptide of a minor Histocompatibility antigen HA-1 origin, comprising the sequence VLXDDLLEA (SEQ ID NO: 1) or an epitope thereof capable of producing an immune response, wherein X is histidine or arginine.

22. (New) The process according to claim 12, wherein the isolated, synthetic or recombinant peptide is flanked by enzymatic cleavage sites.

23. (New) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:2.

24. (New) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:5.

25. (New) The process according to claim 12, further comprising transducing the cytotoxic T-cell with a gene that codes for herpes simplex virus thymidine kinase.